Successful Treatment of Psoriasis Combined with Bullous Pemphigoid with Dupilumab: A Case Report

References

• Kridin K, Ludwig RJ, Schonmann Y, Damiani G, Cohen AD. The bidirectional association between bullous pemphigoid and psoriasis: a population-based cohort study. Front Med. 2020;7:511. doi:10.3389/fmed.2020.00511
   PubMed Web of Science ®Google Scholar
• Ho YH, Hu HY, Chang YT, Li CP, Wu CY. Psoriasis is associated with increased risk of bullous pemphigoid: a nationwide population-based cohort study in Taiwan. J Dermatol. 2019;46(7):604–609. doi:10.1111/1346-8138.14902
   PubMed Web of Science ®Google Scholar
• Phan K, Goyal S, Murrell DF. Association between bullous pemphigoid and psoriasis: systematic review and meta-analysis of case-control studies. Australas J Dermatol. 2019;60(1):23–28. doi:10.1111/ajd.12899
   PubMed Web of Science ®Google Scholar
• Ständer S, Schmidt E, Zillikens D, Thaci D, Ludwig RJ, Kridin K. Patients with bullous pemphigoid and comorbid psoriasis present with less blisters and lower serum levels of anti-BP180 autoantibodies. J Eur Acad Dermatol Venereol. 2021;35(4):981–987. doi:10.1111/jdv.17013
   PubMed Web of Science ®Google Scholar
• Iskandarli M, Gerceker Turk B, Yaman B, Ozturk G. Pemphigoid diseases as a sign of active psoriasis: a case report and brief review. Dermatology. 2015;231(4):319–321. doi:10.1159/000435912
   PubMed Web of Science ®Google Scholar
• Svigos K, Fried L, Yin L, Brinster N, Lo Sicco K, Adotama P. A new eruption of bullous pemphigoid within psoriatic plaques following cyclosporine withdrawal. JAAD Case Rep. 2021;8:23–25. doi:10.1016/j.jdcr.2020.12.001
   PubMedGoogle Scholar
• Wilmer EN, Becker N, Chen A, Kroumpouzos G. Etanercept-induced generalization of chronic, localized, anogenital bullous pemphigoid in a psoriatic patient. JAAD Case Rep. 2016;2(1):25–27. doi:10.1016/j.jdcr.2015.12.006
   PubMedGoogle Scholar
• Sugaya M, Ishii M, Takahashi-Shishido N, Ichimura Y, Morimura S. Case of bullous pemphigoid under treatment with Adalimumab for hidradenitis suppurativa. J Dermatol. 2021;48(4):e163–e164. doi:10.1111/1346-8138.15770
   PubMed Web of Science ®Google Scholar
• Onsun N, Sallahoglu K, Dizman D, Su O, Tosuner Z. Bullous pemphigoid during ustekinumab therapy in a psoriatic patient. Eur J Dermatol. 2017;27(1):81–82. doi:10.1684/ejd.2016.2888
   PubMed Web of Science ®Google Scholar
• Ho P-H, Tsai T-F. Development of bullous pemphigoid during secukinumab treatment for psoriasis. J Dermatol. 2017;44(9):e220–e221. doi:10.1111/1346-8138.13909
   PubMed Web of Science ®Google Scholar
• Minakawa S, Matsuzaki Y, Hashimoto T, et al. Dipeptidyl peptidase-4 inhibitor-associated anti-laminin-γ1 (p200) pemphigoid in a patient with psoriasis vulgaris. J Dermatol. 2020;47(1):e25–e26. doi:10.1111/1346-8138.15126
   PubMed Web of Science ®Google Scholar
• Saraceno R, Citarella L, Spallone G, Chimenti S. A biological approach in a patient with psoriasis and bullous pemphigoid associated with losartan therapy. Clin Exp Dermatol. 2008;33(2):154–155. doi:10.1111/j.1365-2230.2007.02603.x
   PubMed Web of Science ®Google Scholar
• Ruocco V, Sacerdoti G. Pemphigus and bullous pemphigoid due to drugs. Int J Dermatol. 1991;30(5):307–312. doi:10.1111/j.1365-4362.1991.tb03867.x
   PubMed Web of Science ®Google Scholar
• Maronese CA, Cassano N, Genovese G, Foti C, Vena GA, Marzano AV. The intriguing links between psoriasis and bullous pemphigoid. J Clin Med. 2022;12(1):65.
   PubMed Web of Science ®Google Scholar
• Nin M, Tokunaga D, Ishii N, Komai A, Hashimoto T, Katoh N. Case of coexisting psoriatic arthritis and bullous pemphigoid improved by etanercept. J Dermatol. 2013;40(1):55–56. doi:10.1111/j.1346-8138.2012.01659.x
   PubMed Web of Science ®Google Scholar
• Cusano F, Iannazzone SS, Riccio G, Piccirillo F. Coexisting bullous pemphigoid and psoriasis successfully treated with etanercept. Eur J Dermatol. 2010;20(4):520. doi:10.1684/ejd.2010.0970
   PubMed Web of Science ®Google Scholar
• Loget J, Plee J, Antonicelli F, Bernard P. A successful treatment with ustekinumab in a case of relapsing bullous pemphigoid associated with psoriasis. J Eur Acad Dermatol Venereol. 2017;31(5):e228–e230. doi:10.1111/jdv.14002
   PubMed Web of Science ®Google Scholar
• Yun JS, Scardamaglia L, Tan CG, McCormack CJ. Successful secukinumab treatment of active bullous pemphigoid and chronic severe psoriasis: a case report. Australas J Dermatol. 2022;63(2):e155–e158. doi:10.1111/ajd.13803
   PubMed Web of Science ®Google Scholar
• Xiao Y, Gu Y, Xia D, Zhou X, Li W. Ixekizumab successfully treated refractory psoriasis concurrent bullous pemphigoid. J Dermatol. 2023;50(2):e76–e78. doi:10.1111/1346-8138.16559
   PubMed Web of Science ®Google Scholar
• Wang TS, Tsai TF. Remission of bullous pemphigoid after rituximab treatment in a psoriasis patient on regular low-dose methotrexate. Acta Derm Venereol. 2014;94(1):108–109. doi:10.2340/00015555-1619
   PubMed Web of Science ®Google Scholar
• Beck LA, Thaçi D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371(2):130–139. doi:10.1056/NEJMoa1314768
   PubMed Web of Science ®Google Scholar
• Gounni Abdelilah S, Wellemans V, Agouli M, et al. Increased expression of Th2-associated chemokines in bullous pemphigoid disease. Role of eosinophils in the production and release of these chemokines. Clin Immunol. 2006;120(2):220–231. doi:10.1016/j.clim.2006.03.014
   PubMed Web of Science ®Google Scholar
• Guttman-Yassky E, Bissonnette R, Ungar B, et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol. 2019;143(1):155–172. doi:10.1016/j.jaci.2018.08.022
   PubMed Web of Science ®Google Scholar
• Wang Y, Mao X, Liu Y, Yang Y, Jin H, Li L. IL-13 genetic susceptibility to bullous pemphigoid: a potential target for treatment and a prognostic marker. Front Immunol. 2022;13:824110. doi:10.3389/fimmu.2022.824110
   PubMed Web of Science ®Google Scholar
• Abdat R, Waldman RA, de Bedout V, et al. Dupilumab as a novel therapy for bullous pemphigoid: a multicenter case series. J Am Acad Dermatol. 2020;83(1):46–52. doi:10.1016/j.jaad.2020.01.089
   PubMed Web of Science ®Google Scholar
• Liang J, Abulikemu K, Maolidan A, et al. Nine cases of refractory bullous pemphigoid treated with dupilumab and literature review. Int Immunopharmacol. 2023;116:109788. doi:10.1016/j.intimp.2023.109788
   PubMed Web of Science ®Google Scholar
• Wang M, Wang J, Shi B. Case report: dupilumab for the treatment of bullous pemphigoid. Dermatol Ther. 2022;35(7):e15541. doi:10.1111/dth.15541
   PubMed Web of Science ®Google Scholar